Dr Sagun Dawadi
@dr_dawadi
Followers
38
Following
212
Statuses
213
Combat Medico ,Medical officer, Cardiology enthusiast, LVDD, Electrophysiology. https://t.co/XmPgfR7VKe, https://t.co/inBEsxlgVA
Balaju, Kathmandu
Joined March 2022
Excellent interview by our lead author @Prajoli_010 on our recent paper in JSCAI regarding different treatment options for DES- In stent Restenosis. @mesthadb
@SCAI @MyJSCAI
0
1
2
RT @DrMarthaGulati: #HeartMonth has started 💃🏻We #GoRedforWomen this Friday February 7, 2025 💃🏻Go Red for women- the woman you are, the w…
0
39
0
RT @JCVPOnline: Mineralocorticoid Receptor Antagonists in ESRD: Meta-Analysis Insights @dr_dawadi @mesthadb @Prajol…
0
4
0
Hot off the press. Our Network Meta-analysis on different PCI strategies for Coronary DES In stent- Restenosis. @mesthadb
@Prajoli_010
@MyJSCAI
0
3
7
AHA -24
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation: @NEJM 🥸The OPTION trial: @AHAScience 😱 Summary 👇👇👇👇
0
0
0
Wow. Quite intriguing @Prajoli_010 @mesthadb
👀check out this 🇧🇪🇦🇺 collaboration on the the relationship of LVEDV and peak VO2
0
0
1
0
0
0
“There is no need to change the STEMI-NSTEMI paradigm. I never see false negatives.” We published the article “The no false negative paradox in STEMI-NSTEMI diagnosis” in Heart (BMJ), and I’ll explain this paradox with a story: José de Alencar sees a patient with angina. 🧵
0
3
3
1
0
0
RT @NicoGagelmann: Harrison is one of the most amazing teaching books ever produced A short thread on brilliant educational algorithms in…
0
1K
0
RT @drpablocorral: 👉Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women 👏Nice article in @NEJM ☝️ Bu…
0
39
0
#Finerenone in #HeartFailure and Chronic Kidney Disease with T2DM The #FINEHEARTS-HF pooled analysis of cardiovascular, kidney, and mortality outcomes The three trials #FIDELIO-DKD, #FIGARO-DKD, and #FINEARTS-HF; 📍18,991 participants studied over a median of 2.9 years. 📍CV death: 11% ⤵️ with finerenone (HR 0.89; P=0.076). 📍All-cause death: ⬇️ by 9% (HR 0.91; P=0.027). 📍Heart failure 🏥: ⬇️ by 17% (HR 0.83; P<0.001). 📍Kidney outcomes: ⤴️ by 20% (HR 0.80; P<0.001). @mvaduganathan @scottdsolomon @PSJhund
#ESCCongress
0
0
0
Great summary... Yet the question remains. 🧐🧐🧐🧐
Beta-Blocker Interruption or Continuation after Myocardial Infarction: @NEJM 🥸Abyss trial is a very interesting name! 😱30 points summary! 👇👇👇
0
0
0
Can't agree more.☺️
Impactful study - Perhaps (HOPEFULLY) the final nail in the coffin as to why it is absurd to use the term GOOD CHOLESTROL - any clinician using that archaic term should lose their license
0
0
0
No more Sc in AF.
Female gender was removed from CHADS-VASc score in new ESC guidelines for management of AF. Rationale : female gender is a risk modifier rather than risk factor for stroke. Now we have a CHADS-VA score.
0
0
0
#Aficamten 5/6 presentation In this innovative NT-proBNP/hs-troponin analysis (#SEQUOIA-HCM, afi vs placebo in oHCM) @carolinecoats and @JJheart_doc show novel data on these biomarkers in obstructive #HCM Simultaneous pub in @ESC_Journals
#ESCCongress
#CardioTwitter
0
0
0